Advocating Targeted Sequential Screening over Whole Exome Sequencing in 21-Hydroxylase Deficiency
Indian Journal of Pediatrics · 2025
DOI: 10.1007/s12098-024-05249-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Pediatrics, 2025. Verfasst von Lavanya Ravichandran und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, India. Hauptthemen laut MEDLINE: Adrenal Hyperplasia, Congenital, Steroid 21-Hydroxylase, Exome Sequencing, Genetic Testing. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Indian Council of Medical Research.
Abstract (Originalsprache)
OBJECTIVES: Whole exome sequencing (WES) has emerged as the preferred method for diagnosing a range of Mendelian disorders. Nonetheless, the applicability of WES in genetic diagnosis of 21-hydroxylase deficiency (21-OHD) remains uncertain due to the intricacies involved in molecular analysis of the CYP21A2 gene. METHODS: In this case series, authors report the outcomes of couples or families who underwent WES followed by focused sequential strategy (FSS) targeting CYP21A2 gene hotspot mutations and targeted sequencing of genes associated with Congenital Adrenal Hyperplasia (CAH). RESULTS: This analysis revealed that WES, when compared to FSS, resulted in six false-negative findings out of seven subjects and one false-positive result. These results were corroborated through validation using Multiplex Ligation-Dependent Probe Amplification (MLPA) and Sanger sequencing. CONCLUSIONS: One major limitation of exome sequencing lies in target enrichment, which often achieves less than 95% coverage of the regions of interest, potentially leading to false negatives. This challenge is particularly pronounced when deciphering the complex genetics of 21-OHD, characterized by intricate pseudogene-derived rearrangements and gene conversions. Additionally, next-generation sequencing (NGS) analysis of the CYP21A2 gene is not straightforward due to reads aligning to pseudogene regions, necessitating stringent computational pipelines with defined targets. However, simple genotyping assays have shown a high positive yield of pseudogene-derived mutations in over 80% of cases, while targeted NGS can be valuable in subjects with initially negative results. Therefore, WES is not recommended as the primary testing method for 21-OHD and may be better suited for rare forms of CAH once CYP21A2 mutations have been ruled out.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, India.
- Department of Medical Genetics, Christian Medical College, Vellore, India.
- Department of Pediatric Endocrinology, Christian Medical College, Vellore, India.
- Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, India. aaronchapla@gmail.com.
ORCID-Profile: Aaron Chapla
Förderung
- Indian Council of Medical Research
Zitieren
APA
Ravichandran, L., Paul, S., Rekha, A., Varghese, D., Parthiban, R., Asha, H. S., Mathai, S., Simon, A., Danda, S., Thomas, N., & Chapla, A. (2025). Advocating Targeted Sequential Screening over Whole Exome Sequencing in 21-Hydroxylase Deficiency. Indian Journal of Pediatrics. https://doi.org/10.1007/s12098-024-05249-0
Vancouver
Ravichandran L, Paul S, Rekha A, Varghese D, Parthiban R, Asha HS, et al. Advocating Targeted Sequential Screening over Whole Exome Sequencing in 21-Hydroxylase Deficiency. Indian Journal of Pediatrics. 2025. doi:10.1007/s12098-024-05249-0
BibTeX
@article{Ravichandran2025,
author = {Ravichandran, Lavanya and Paul, Shriti and Rekha, A and Varghese, Deny and Parthiban, R and Asha, H S and Mathai, Sarah and Simon, Anna and Danda, Sumita and Thomas, Nihal and Chapla, Aaron},
title = {Advocating Targeted Sequential Screening over Whole Exome Sequencing in 21-Hydroxylase Deficiency},
journal = {Indian Journal of Pediatrics},
year = {2025},
doi = {10.1007/s12098-024-05249-0}
}
EUVIMED